Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||8%|
|1 Day Vol Adjusted Return||-0.4|
|1 Month Vol Adjusted Return||1.3|
|3 Month Vol Adjusted Return||28.0|
|6 Month Vol Adjusted Return||28.4|
|20 Days SMA Price ZScore||1.1|
|50 Days SMA Price ZScore||1.0|
|12 -26 Days PPO||6.7|
|1 Month Average Short Volume Ratio||42.7|
|1 Day Volume Change ZScore||0.1|
|1 Month Daily Vol||8.8|
The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. In this case, Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B.
Upgrades According to Ladenburg Thalmann, the prior rating for Invitae Corp (NYSE:NVTA) was changed from Neutral to Buy. For the fourth quarter, Invitae had an EPS of $0.63, compared to year-ago quarter EPS of $0.63. At the moment, the stock has a 52-week-high of $61.59 and a 52-week-low of $7.42. Invitae closed at $47.87 at the end of the last trading period. According to Maxim Group, the prior rating for Titan Pharmaceuticals Inc (NASDAQ:TTNP) was changed from Hold to Buy. The current stock pe...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, VistaGen Therapeutics...
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD) Strengthened Balance Sheet upon closing of $100 million underwritten public offering SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines wit...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, announced today that it received notice from The Nasdaq Stock Market (Nasdaq) on January 5, 2021 that VistaGen has regained compliance with the minimum bid price requirement un...